Company

Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics is a Massachusetts-based biotech company developing molecular glue degraders for cancer and autoimmune diseases.

About

Founded in 2018 and based in Massachusetts, US, Monte Rosa Therapeutics, Inc. develops molecular glues to treat cancer and autoimmune diseases, using its QuEEN protein degradation platform to design small molecules that reprogram ubiquitin ligases to eliminate disease drivers. CEO Markus Warmuth led the company as of 2021. In June 2021 it raised USD 222.3 million in an IPO, selling 11.7 million shares at USD 19 per share on Nasdaq under the ticker GLUE, after raising total funding of USD 223.5 million as of March 2021.

4Funding rounds

15Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in